Company Overview of Therapix Biosciences Ltd.
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.
5 Azrieli Center (Square Tower)
Tel Aviv, 6702501
Founded in 2004
972 3 616 7055
972 3 616 7056
Key Executives for Therapix Biosciences Ltd.
Therapix Biosciences Ltd. Key Developments
Similar Private Companies By Industry
|3PLW Ltd.||Middle East/Africa|
|Accelerated Evolution Biotechnologies Ltd||Middle East/Africa|
|Adante Ltd.||Middle East/Africa|
|Advanced Biotechnology Ltd.||Middle East/Africa|
|Advanced Medical Analysis (AMA) Ltd.||Middle East/Africa|
Recent Private Companies Transactions
February 14, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Therapix Biosciences Ltd., please visit www.therapixbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.